Technology | Cath Lab | February 07, 2018

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

Latest versions of 0.035-inch snares offer clinical versatility in retrieving or repositioning intravascular devices for peripheral procedures

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

February 7, 2018 — Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch of new versions of its Expro Elite and Sympro Elite Snares for manipulating interventional devices in peripheral procedures.

Both the Expro Elite and Sympro Elite Snares represent next-generation versions of the 0.035-inch interventional snares originally launched in the U.S. in 2008 by Vascular Solutions, now a wholly-owned subsidiary of Teleflex Inc.

Stewart Strong, president and general manager of the Interventional business unit of Teleflex, said both snare products feature:

  • A durable nitinol construction that retains its shape and adds strength;
  • A radiopaque gold-plated tungsten coil and tip for enhanced visibility;
  • 1:1 torque response for controlled positioning and better access to distal targets; and
  • A unique locking handle that facilitates secure capture.

The Expro Elite Snare uses a helical loop for capture in all directions. The Sympro Elite Snare uses a 90-degree loop that remains coaxial to the vessel lumen for easy capture. Both snare products feature a preassembled, one-piece design that allows rapid deployment through any 0.035-inch compatible lumen. Both the Expro Elite and Sympro Elite Snares are available in 5, 10, 15, 25 and 35 mm loop diameters for clinical versatility. Both snares are 150 cm in length and are packaged one per box.

Both snares are intended for use in the cardiovascular system and hollow viscus to retrieve and/or manipulate objects using minimally-invasive surgical procedures. Manipulation procedures include retrieval and/or repositioning of intravascular foreign objects such as coils, balloons, catheters, and/or guidewires within the cardiovascular system. The devices are not intended for use in the coronary arteries or neurovasculature.

For more information: www.teleflex.com

 

Related Content

SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab | October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Overlay Init